Red yeast rice is most commonly taken by mouth to lower cholesterol.
The active ingredient in red yeast rice is the same as one of the active ingredients in prescription drugs called statins. Statins are used for high cholesterol. That's why red yeast rice has all the same possible side effects, drug interactions, and precautions as statins. You should talk with your healthcare provider if you plan to take red yeast rice.
How does it work ?
Uses & Effectiveness ?
Likely Effective for
- High levels of cholesterol or other fats (lipids) in the blood (hyperlipidemia). Research shows that taking red yeast rice products for up to 6 months can lower total cholesterol, low-density lipoprotein (LDL or "bad") cholesterol, and triglycerides. But these red yeast rice products contain the same chemical as the "statin" drug lovastatin. Statins are approved by the U.S. Food and Drug Administration (FDA) to lower cholesterol. The FDA considers red yeast rice products that contain statins to be illegal unapproved drugs. But many of these products are still available. Some red yeast rice products available in the U.S. contain little or no statins. It is not known if these red yeast rice products can reduce cholesterol levels.
Possibly Effective for
- Abnormal levels of blood fats in people with HIV/AIDS. Taking red yeast rice by mouth seems to reduce cholesterol and triglyceride levels in people with HIV infection.
- Heart attack. Taking 1.2 grams of red yeast rice extract daily for an average of 4.5 years decreases the risk of heart attacks and death in people with a history of heart attack.
Possibly Ineffective for
- High blood pressure. Taking red yeast rice combined with prescription blood pressure-lowering drugs does not seem to reduce blood pressure more than taking prescription blood pressure-lowering drugs alone.
Insufficient Evidence for
- Cancer. Some clinical research shows that taking red yeast rice daily for about 4.5 years may reduce the risk of dying from cancer. But it's not known if red yeast rice reduces the risk of developing cancer.
- Recovery after surgery. People who take red yeast rice prior to undergoing inpatient surgery seem to have a lower chance of death, bleeding, pneumonia, stroke, and other complications of surgery.
- Heart disease.
- A grouping of symptoms that increase the risk of diabetes, heart disease, and stroke (metabolic syndrome).
- Build up of fat in the liver in people who drink little or no alcohol (nonalcoholic fatty liver disease or NAFLD).
- Improving blood circulation.
- Spleen and stomach problems.
- Other conditions.
Red yeast rice contains chemicals that are the same as the prescription drugs called "statins." Therefore, red yeast might also cause side effects similar to statin drugs, such as liver damage and severe muscle pain and muscle damage.
There is also concern about product quality. Many red yeast rice products have been found to have different amounts of the statin-type chemicals. Some products may contain none and others may contain high amounts, which are more likely to cause serious side effects.
Red yeast rice that is not fermented correctly may contain citrinin. Citrinin is a poison that may cause kidney damage.
Special Precautions & Warnings:Pregnancy and breast-feeding: Red yeast rice is LIKELY UNSAFE when taken by mouth during pregnancy. Some chemicals in red yeast rice have caused birth defects in animals. Not enough is known about the safety of using red yeast rice during breast-feeding. Don't use during pregnancy or breast-feeding.
Liver problems: Red yeast rice contains chemicals that are the same as the statin drug lovastatin. Lovastatin can cause liver damage. Some research shows that red yeast rice might also cause liver damage to the same degree as lovastatin. However, other research shows that red yeast rice might not cause liver problems and might improve liver function in people with certain liver problems. Because of the mixed results, red yeast rice products should be used cautiously or avoided in people with liver problems.
Special Precautions and Warnings
We currently have no information for RED YEAST RICE overview.
Alcohol interacts with RED YEAST RICE
Drinking alcohol might harm the liver. Red yeast might also harm the liver. Taking red yeast along with alcohol might increase the risk of liver damage. Do not drink alcohol if you are taking red yeast.
Cyclosporine (Neoral, Sandimmune) interacts with RED YEAST RICE
Red yeast might affect the muscles. Cyclosporine (Neoral, Sandimmune) might also affect the muscles. Taking red yeast along with cyclosporine (Neoral, Sandimmune) might cause serious side effects.
Gemfibrozil (Lopid) interacts with RED YEAST RICE
Gemfibrozil (Lopid) can affect the muscles. Red yeast can also affect the muscles. Taking gemfibrozil along with red yeast might increase the risk of muscle problems.
Medications used for lowering cholesterol (Statins) interacts with RED YEAST RICE
Red yeast can help lower cholesterol. Taking red yeast along with other medications used to lower cholesterol might increase the risk of adverse effects. Do not take red yeast if you are already taking medications used for lowering cholesterol.
Some medications used for high cholesterol include cerivastatin (Baycol), atorvastatin (Lipitor), lovastatin (Mevacor), pravastatin (Pravachol), simvastatin (Zocor), and others.
Medications that decrease the break down of other medications in the liver (Cytochrome P450 3A4 (CYP3A4) inhibitors) interacts with RED YEAST RICE
Some medications are changed and broken down by the liver.
Some medications might decrease how quickly the liver breaks down red yeast. Taking red yeast along with some medications that decrease the breakdown of other medications in the liver can increase the effects and side effects of red yeast. Before taking red yeast, talk to your healthcare provider if you are taking any medications that are changed by the liver.
Some medications that might decrease how quickly the liver breaks down red yeast include amiodarone (Cordarone), clarithromycin (Biaxin), diltiazem (Cardizem), erythromycin (E-mycin, Erythrocin), indinavir (Crixivan), ritonavir (Norvir), saquinavir (Fortovase, Invirase), and many others.
Medications that can harm the liver (Hepatotoxic drugs) interacts with RED YEAST RICE
Red yeast contains the statin drug lovastatin. Lovastatin might harm the liver in some people. Taking red yeast along with other medications that might also harm the liver might increase the risk of liver damage. Do not take red yeast if you are taking another medication that can harm the liver.
Some medications that can harm the liver include acetaminophen (Tylenol and others), amiodarone (Cordarone), carbamazepine (Tegretol), isoniazid (INH), methotrexate (Rheumatrex), methyldopa (Aldomet), fluconazole (Diflucan), itraconazole (Sporanox), erythromycin (Erythrocin, Ilosone, others), phenytoin (Dilantin), lovastatin (Mevacor), pravastatin (Pravachol), simvastatin (Zocor), and many others.
Niacin interacts with RED YEAST RICE
Niacin can affect the muscles. Red yeast can also affect the muscles. Taking niacin along with red yeast might increase the risk of muscle problems.
Be cautious with this combination
- High levels of cholesterol or other fats (lipids) in the blood (hyperlipidemia): 1200 mg to 2400 mg of red yeast rice once or twice daily for up to 4.5 years. Only products containing chemicals like the prescription "statin" cholesterol drugs have been shown to lower cholesterol levels. Many of these products provide approximately 5-10 mg of the statin drug called lovastatin and may contain other ingredients. These products have included Cholestin (non-US, Pharmanex), Xuezhikang (Beijing WBL Peking University Biotech Co.), HypoCol (AsiaPharm Biotech), Zhibituo, and Red Yeast Rice (Sylvan Bioproducts). Red yeast rice products containing statins are considered illegal in the U.S.
- Abnormal levels of blood fats in people with HIV/AIDS: 1200 mg of a specific red yeast rice formulation (Cholestin, Pharmanex LLC) twice daily for 8 weeks.
- Heart attack: A specific product (Xuezhikang, Beijing Peking University WBL Biotech Co., Ltd.) containing 1200 mg of red yeast rice extract daily for about 4.5 years.
Affuso, F., Ruvolo, A., Micillo, F., Sacca, L., and Fazio, S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc.Dis 2010;20(9):656-661. View abstract.
Babitha, S., Soccol, C. R., and Pandey, A. Solid-state fermentation for the production of Monascus pigments from jackfruit seed. Bioresour.Technol. 8-17-2006; View abstract.
Becker, D. J., Gordon, R. Y., Morris, P. B., Yorko, J., Gordon, Y. J., Li, M., and Iqbal, N. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin.Proc. 2008;83(7):758-764. View abstract.
Bi JZ, Ma SZ Li YQ. Observations on the therapeutic effects of Diao Zhibituo for treatment of hyperlipidemia. Shiyong Zhongxiyi jiehe Zazhi 1996;9(12):729.
Blanc, P. H., Loret, M. O., Santerre, A. L., Pareilleux, A., Prome, D., Prome, J. C., Laussac, J. P., and Goma, G. Pigments of Monascus. J.Food Sci. 1994;59:862-865.
Bonovich, K., Colfer, H., Petoskey, M. I., and et al. A multi-center, self-controlled study of cholestin in subjects with elevated cholesterol. Journal of Investigative Medicine 1999;47(2):54A.
Cai MX, Deng JX Lu LF. : Clinical observations on Diao Zhibituo for treatment of hyperlipidemia. Fujian Yiyao Zazhi 1997;19(2):83-84.
Campoy, S., Rumbero, A., Martin, J. F., and Liras, P. Characterization of an hyperpigmenting mutant of Monascus purpureus IB1: identification of two novel pigment chemical structures. Appl.Microbiol.Biotechnol 2006;70(4):488-496. View abstract.
Chagas, G. M., Kluppel, M. L., Campello, Ade P., Buchi, Dde F., and de Oliveira, M. B. Alterations induced by citrinin in cultured kidney cells. Cell Struct.Funct. 1994;19(2):103-108. View abstract.
Chang, J. C., Wu, M. C., Liu, I. M., and Cheng, J. T. Plasma glucose-lowering action of Hon-Chi in streptozotocin-induced diabetic rats. Horm.Metab Res 2006;38(2):76-81. View abstract.
Chen FJ, Ruan Q Qi HW Yuan PY. Clinical observation of Xuezhikang in treating middle and old age hyperlipidemia. Shanghai Yufangyixue Zazhi 2003;15(5):222-223.
Chen GY. Observations on the therapeutic effects of Zhibituo for treatment of hyperlipidemia in the elderly. Guizhou Yiyao 1999;23(4):307-308.
Chen JF, Yan ZZ Li PT. Comparison of Zhibituo and Duoxikang for treatment of hyperlipidemia. 1997, 16(1):15-17. Zhongguo Xinyao Yu Linchuang Zazhi 1997;16(1):15-17.
Chen L, Qin YW Guo RB. Clinical efficacy of capsule Xuezhikang in treatment of hypercholesterolemia. Yaoxue Fuwu Yu Yanjiu 2002;2(1):39-40.
Chen L, Qin YW Zheng X. Effects of lipid modification of Diao Zhibituo capsules. Zhongguo Zhongxiyi Jiehe Zazhi 2003;23(5):389.
Chen LL, Liu J. Effects of Xuezhikang on hypercholesterolemia. Yiyao Daobao 2002;21(1):31-32.
Chen LL, Liu J. The lipid regulation function of Xuezhikang on hypercholesterolemia. Herald of Medicine 2002;21(1):31-32.
Chen ZL. Controlled study of Diao Zhibituo and alginic sodium diester for lipid lowering effect. Henan Shiyong Shenjingbing Zazhi 1998;1(2):20.
Chen ZM. Comparison of the therapeutic effects of simvastatin and Zhibituo for treatment of hyperlipidemia. Guangxi Yike Daxue Xuebao 2001;18(4):543.
Chen, C. C. and Liu, I. M. Release of acetylcholine by Hon-Chi to raise insulin secretion in Wistar rats. Neurosci.Lett 8-14-2006;404(1-2):117-121. View abstract.
Cheng XM, Yu ZM Luo HD Qiu YH Chen MX. Effect of Xuezhikang on endothelial function in patients with hyperlipidemia. Chin J Arterioscler 2001;9(3):235-237.
China Coronary Secondary Prevention Study Group. China coronary secondary prevention study (CCSPS). Lipid regulating therapy with xuezhikang for secondary prevention of coronary heart disease. Chin J Cardiol (Chin) 2005;33:109-115.
Cicero, A. F., Brancaleoni, M., Laghi, L., Donati, F., and Mino, M. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med 2005;13(4):273-278. View abstract.
Cong B. Observations on the therapeutic effects of Zhibituo for treatment of hyperlipidemia. Hebei Yiyao 1999;5(3):60-61.
Deng YM, Meng MK Liao YZ. Clinical observation of Xuezhikang on treatment of elderly patients with primary mixed hyperlipidemia. Chinese Journal of Gerontology 2006;26(11):1566-1567.
Deng, J., Yun, L., and Peng, C. Clinical observations of xuezhikang on acute myocardial infarction patients with hyperlipoidemia. Journal of Capital Medicine 2000;7(1):42-43.
Ding W, Zhou Y. Xuezhikang on treatment of hypercholesterolemia. China Medical News 1999;32(21):21.
Fan, X. F., Deng, Y. Q., Ye, L., Li, Y. D., Chen, J., Lu, W. W., and Li, J. P. Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chin J.Integr.Med. 2010;16(2):119-123. View abstract.
Feng JC, Wang JS Wang CP Jiang YJ Tan GZ. Effects of conjugated estrogen and Xuezhikang in low dosage on blood lipid in postmenopausal women. 2000, 9(23):2334-5. Xiandai Zhongxiyi jiehe Zazhi 2000;9(23):2334-2335.
Feng XY, Wang XF Li X. Analysis of 116 cases of hyperlipemia in treatment with Xuezhikang. Medical Information 2006;19(3):512-513.
Feuerstein, J. S. and Bjerke, W. S. Powdered red yeast rice and plant stanols and sterols to lower cholesterol. J.Diet.Suppl 2012;9(2):110-115. View abstract.
Fu G, Liu WJ Wang GT. Comparison of Zhibituo and fish oil capsules for treatment of hyperlipidemia. Heilongjiang Yiyao 2000;23(5):93-94.
Gu ZY, Lu ZF Zhu HQ. Observations on the therapeutic effects of Zhibituo for treatment of 158 patients with hyperlipidemia. Nantong Yixueyuan Xuebao 1998;18(3):374-375.
Guardamagna, O., Abello, F., Baracco, V., Stasiowska, B., and Martino, F. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr.Metab Cardiovasc.Dis. 2011;21(6):424-429. View abstract.
Guo WC, Feng WJ. Clinical observations of statin alone or combined with unsaturated fatty acids for the treatment of combined hyperlipidemia in elderly people. Beijing Yixue 2003;25(1):25-27.
Guo XL, Li Y Yin GN. Xuezhikang for treatment of 30 cases of hyperlipidemia. Ningxia Yixue Zazhi 1999;21(7):418.
Guo XM, Tu L Mi S. Comparison of the therapeutic effects of Zhibituo and simvastatin for regulating dyslipidemia. Zhongyao Yaoli Yu Linchuang 1999;15(6):46-48.
Hasani-Ranjbar, S., Nayebi, N., Moradi, L., Mehri, A., Larijani, B., and Abdollahi, M. The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review. Curr.Pharm.Des 2010;16(26):2935-2947. View abstract.
Havel, R. J., Hunninghake, D. B., Illingworth, D. R., Lees, R. S., Stein, E. A., Tobert, J. A., Bacon, S. R., Bolognese, J. A., Frost, P. H., Lamkin, G. E., and . Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann.Intern.Med 1987;107(5):609-615. View abstract.
Heber D, Yip I, Ashley J, and et al. A chinese red yeast rice dietary supplement significantly reduces cholesterol levels [ abstract]. FASEB J 1998;12:1201.
Hua D. Comparative Observation of simvastatin and Xuezhikang for patients with hyperlipidemia. Herbei Medicine 2008;14(7):879-881.
Huang GZ, Yang S Wu ZG. Observation on therapuetic effect of Zhibituo for treatment of hyperlipidemia. Dier Junyi Daxue Xuebao 1998;19(1):94-95.
Huang LJ, Chen MS. Comparison of Diao Zhibituo and Inositol nicotinate for the lipid lowering effects. Zhongyuan Yikan 1997;24(1):8-10.
Huang YL, Zhou JG Zhang HF Shi YX Wang MS. Comparison of the therapeutic effects of simvastatin and Zhibituo for the elderly with hyperlipidemia. Yixue Yu Gongcheng 2001;3(1):24-27.
Jeon, T., Hwang, S. G., Hirai, S., Matsui, T., Yano, H., Kawada, T., Lim, B. O., and Park, D. K. Red yeast rice extracts suppress adipogenesis by down-regulating adipogenic transcription factors and gene expression in 3T3-L1 cells. Life Sci. 11-12-2004;75(26):3195-3203. View abstract.
Jian, J., Hao, X., Deng, C., Zhou, H., and Lin, J. [The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia]. Zhonghua Nei Ke.Za Zhi. 1999;38(8):517-519. View abstract.
Jiang HP. Comparison of the therapeutic effects and compliance of Xuezhikang and Fenofibrate in patients with hyperlipidemia. Xiandai Zhenduan Yu Zhiliao 2001;12 (Suppl):29.
Jin W, Yang H Zhang C Zhang CJ Xu YH. Therapeutic observations of Xuezhikang for treatment of primary hyperlipidemia. Zhongguo Zhongxiyi Jiehe Zazhi 1997;17(7):434-435.
Jin WQ, Li CW Xu M Gao YX Xu XW. Comparison of Zhibituo and Duoxikang in treating 108 patients with hyperlipidemia. Zhongguo Xinyao Yu Linchuang Zazhi 1997;16(1):61-62.
Jung, H., Kim, C., Kim, K., and Shin, C. S. Color characteristics of monascus pigments derived by fermentation with various amino acids. J Agric.Food Chem 2-26-2003;51(5):1302-1306. View abstract.
Kong YM, Gao H Liu XL. Clinical observations of the lipid-lowering effects of Xuezhikang and elastase. Zhongguo Yaoshi 1999;8(3):56.
Krejci, M. E., Bretz, N. S., and Koechel, D. A. Citrinin produces acute adverse changes in renal function and ultrastructure in pentobarbital-anesthetized dogs without concomitant reductions in [potassium] plasma. Toxicology 1-8-1996;106(1-3):167-177. View abstract.
Kucsera, J., Pfeiffer, I., and Ferenczy, L. Homothallic life cycle in the diploid red yeast Xanthophyllomyces dendrorhous (Phaffia rhodozyma). Antonie Van Leeuwenhoek 1998;73(2):163-168. View abstract.
Kuramoto, Y., Yamada, K., Tsuruta, O., and Sugano, M. Effect of natural food colorings on immunoglobulin production in vitro by rat spleen lymphocytes. Biosci.Biotechnol.Biochem. 1996;60(10):1712-1713. View abstract.
Lee, C. L., Wang, J. J., and Pan, T. M. Synchronous analysis method for detection of citrinin and the lactone and acid forms of monacolin K in red mold rice. J AOAC Int 2006;89(3):669-677. View abstract.
Lee, I. T., Lee, W. J., Tsai, C. M., Su, I. J., Yen, H. T., and Sheu, W. H. Combined extractives of red yeast rice, bitter gourd, chlorella, soy protein, and licorice improve total cholesterol, low-density lipoprotein cholesterol, and triglyceride in subjects with metabolic syndrome. Nutr Res 2012;32(2):85-92. View abstract.
Lei HZ. Effects of Xuezhikang on endothelial function in aged patients with hyperlipidemia. Guangxi Yixue 2004;26(4):495-497.
Li BH, Zheng GJ Zhang WG Xu M Ren P. Clinical observations of Ruanmaijianzhi capsule in the treatment of dyslipidemia. Hebei Zhongyi Zazhi 2004;26(9):657-659.
Li DX, Li YF Lu HY. Comparison of the effects of Xuezhikang with inositol hexanicotinate on lipid profile modification. Henan Zhigong Yixueyuan Xuebao 2000;12(1):17-18.
Li FL, Zeng WH. Comparison of Zhibituo and Inositol nicotinate for treatment of hyperlipidemia. Nongken Yixue 2002;24(3):198-199.
Li GR, Li JP Mai WY Zeng Y. Micronised fenofibrate for treatment of mixed type of hyperlipidemia. Guangdong Yixue 1999;20(11):895-896.
Li KL. Comparison study on the effect of Xuezhikang and simvastatin for treatment of primary hypercholesterolemia. China Medical Herald 2006;3(17):22-23.
Li LH, Deng GL Chen YZ. CIinical comparative study of simvastatin and Xuezhikang and pravastatin in common doses on primary hyperlipidemia. Journal of Chongqing Medical University 2005;30(2):278-284.
Li Y, Min YB Fan XJ. Comparison of the therapeutic effects of Zhibituo and fish oils for treatment of 30 cases of hyperlipidemia. Guangdong Yaoxue Zazhi 2000;10(1):43-45.
Li YM, Sun RX. Therapeutic observations on Xuezhikang for treatment of hyperlipidemia. Zhongguo Shiyong Xiangcun Yisheng Zazhi 2004;11(8):25-26.
Li YS, Lei HZ Zhu MJ. Clinical observations of 41 cases of elderly with hyperlipidemia treated with Xuezhikang. Zhongguo Quanke Yixue 2003;6(2):163.
Li, C., Zhu, Y., Wang, Y., Zhu, J. S., Chang, J., and Kritchevsky, D. Monascus purpureus-fermented rice (red yeast): a natural food product that lowers blood cholesterol in animal models of hypercholesterolemia. Nutrition Res. 1998;18:71-81.
Li, J. J., Hu, S. S., Fang, C. H., Hui, R. T., Miao, L. F., Yang, Y. J., and Gao, R. L. Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim.Acta 2005;352(1-2):217-224. View abstract.
Li, J., Tatsanavivat, P., Wang, J., and et al. Comparison of the efficacy and safety of xuezhikang and lovastatin in hyperlipidemic patients with hypertension [abstract]. Global Meeting ICLEN XVI, March 1999;
Li, Q. L. and Zhang, Y. F. [Clinical observation on effect of taizhi'an capsule in treating 150 patients with hyperlipidemia]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 2003;23(5):335-337. View abstract.
Li, Z., Seeram, N. P., Lee, R., Thames, G., Minutti, C., Wang, H. J., and Heber, D. Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. J Altern Complement Med 2005;11(6):1031-1038. View abstract.
Liao, C. C., Huang, C. L., Su, K. P., Chang, Y. H., and Lin, C. C. Red Yeast Rice for a patient with olanzapine-induced dyslipidemia: a test-and-retest case report. Prog.Neuropsychopharmacol.Biol.Psychiatry 7-1-2008;32(5):1340-1341. View abstract.
Lin, W. Y., Song, C. Y., and Pan, T. M. Proteomic analysis of Caco-2 cells treated with monacolin K. J Agric.Food Chem 8-23-2006;54(17):6192-6200. View abstract.
Liu L, Li JP Shen PN. Clinical observations of Xuezhikang for treatment of mixed type of hyperlipidemia. Zhonghua Shiyong Yixue 2000;16(12):1047-1048.
Liu ZB. Xuezhikang for treatment of 40 cases of hyperlipidemia. Linchuang Huicui 1998;13(8):367-368.
Liu, B. H., Wu, T. S., Su, M. C., Chung, C. P., and Yu, F. Y. Evaluation of citrinin occurrence and cytotoxicity in Monascus fermentation products. J Agric.Food Chem. 1-12-2005;53(1):170-175. View abstract.
Liu, X. D., Wang, M., and Li, Y. Z. [Clinical observation on acupoint catgut embedding for treatment of non-alcoholic steatohepatitis]. Zhongguo Zhen.Jiu. 2010;30(8):637-641. View abstract.
Liu, Y. and Zhao, J. B-mod ultrasonogram change of 276 cases of fatty liver patients treated by xuezhikang. Chinese Journal of Internal Medicine 1999;38(8):554-555.
Liu, Z. and Zhang, Y. Clinical observation of treatment of hyperlipidemia with Xuezhikang. Clin Med News 1996;11:12-13.
Liu, Z. M., Li, Z., Zhang, H., and et al. The clinical observation of the medical treatment for hyperlipidemia with Xuezhikang. Unpublished data, reported by Institute for Natural Products Research (INPR) 2001;
Liu. Pharmanex report: PN0128. 1997;
Lu GP, Huo ShQ. Comparison of the effects of Xuezhikang with simvastatin on lipid profile modification in patients with hypercholesterolemia. Chinese Journal of Internal Medicine 1998;37(6):371-373.
Lu GP, Huo SQ Shen YC Gong LS. Comparison of the effects of Xuezhikang with simvastatin on lipid profile modification in patients with hypercholesterolemia. Zhonghua Neike Zazhi 1998;37(6):371-373.
Lu WX, Wang JX Zhu JG Xu DS Yang MJ Wang HW Wang RZ Zheng R. Zhibituo capsules in treatment of hyperlipidemia: a multi-centre clinical trial. Zhongguo Xinyao Yu Linchuang Zazhi 1999;18(6):365-367.
Lu YS, Gu JS Zhou WG. Comparison of the therapeutic effects of Xuezhikang and Zhibituo in treatment of adults with hyperlipidemia. Zhongguo Zhongxiyi Jiehe Zazhi 1998;18(8):467.
Lu, G. and Gong, L. The comparison of hypolipidemic effects of Xue-Zhi-Kang and simvastatin on patients with hypercholesterolemia. Scientific Report Number PN0134
Lu, Z. L., Xu, S., and Kou, W. R. The clinical observation of treatment of hyperlipidemia with different dose of Xuezhikang. National Symposium of Clinical Therapies for Cardiovascular Diseases 1995;1997:53-57.
Lu, Z. The clinical examinations of Xue-Zhi-Kang in the treatment for hypercholesterolemia. Beijing University, Wei-Xin data 2002;
Ma F, Ma XH. Clinical observation of Finofibrate and Xuezhikang for treatment of hyperlipidemia. Zhongguo Hangtianye Yiyao 2003;5(1):55-56.
Ma L, Gao Y Li BZ. Observations of the therapeutic effects of Zhibituo for treatment of 50 patients with hyperlipidemia. Xibei Yaoxue Zazhi 2000;15(3):126.
Ma YL. Observation of 30 cases of hypercholesterolemia in treatment with Xuezhikang. Journal of Practical Traditional Chinese Medicine 2002;18(3):48.
Man, R. Y., Lynn, E. G., Cheung, F., Tsang, P. S., and O K. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Mol Cell Biochem 2002;233(1-2):153-158. View abstract.
Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., and Rosano, G. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv.Ther 2011;28(12):1105-1113. View abstract.
Martinkova, L., Patakova-Juzlova, P., Krent, V., Kucerova, Z., Havlicek, V., Olsovsky, P., Hovorka, O., Rihova, B., Vesely, D., Vesela, D., Ulrichova, J., and Prikrylova, V. Biological activities of oligoketide pigments of Monascus purpureus. Food Addit.Contam 1999;16(1):15-24. View abstract.
O'Mathuna DP. Cholestin used to treat hypercholesterolemia. Drug Utilization Review 1999;15(5):71-75.
Ong, H. T. and Cheah, J. S. Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics. Chin Med.J.(Engl.) 8-20-2008;121(16):1588-1594. View abstract.
Lakey WC, Greyshock N, Guyton JR. Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants. J Clin Lipidol. 2013 Mar-Apr;7(2):178-81. View abstract.
Lal SM, Hewett JE, Petroski GF, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis 1995;25:616-22. View abstract.
Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013 Jan 29;61(4):440-6. View abstract.
Leighton RF, Gordon NF, Small GS, et al. Dental and gingival pain as side effects of niacin therapy. Chest 1998;114:1472-4. View abstract.
Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med. 1989;86(4):481-3. View abstract.
Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med. 1989;86(4):481-3.View abstract.
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert consensus decision rathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll of Cardiol 2016;68(1):92-125. View abstract.
Peng DY. Observation on the effect of Zhibituo in treating hyperlipidemia. Zhongguo Yejin Gongye Yixue Zazhi 1998;15(4):201-203.
Pisciotta, L., Boscarini, M., and Corio, R. Studi clinici su Normolip5, integratore alimentare per il controllo del colesterolo. Medicina Naturale 2004;68-70.
Qi MY, Z J X JG. Clinical observation of Xuezhikang on treatment of 112 cases of hypercholesterolemia. Practical Clinical Medicine (Jiangxi) 2004;5(6):20-22.
Qi P, Huang Y Deng J. Effects of Xuezhikang vs. Inositol niacinate in treating hyperlipidemia. Jiangxi Yixueyuan Xuebao 2002;42(4):24-25.
Qin SC, Zhang WQ Qi P Zhao ML Dong ZN Li YC Xu XM Fang X Fu L. Randomized, double blind, controlled trial for the clinical therapeutic effects of Xuezhikang in the elderly with hyperlipidemia. Zhonghua Neike Zazhi 1998;37(6):401-402.
Qin, S., Zhang, W., Qi, P., and et al. Elderly patients with primary hyperlipidemia benefited from treatment with a Monascus purpureus rice preparation: A placebo-controlled, double-blind clinical trial. Abstracts of the 39th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, March 24-27 1999;99:1123 (Abstract P89).
Qiu JP, Wang ZJ Xu XP Ma SY Kuang RJ. Observations of Zhibituo on the therapeutic effects in treatment of 60 patients with hyperlipidemia. Shandong Yiyao 2002;42(6):45-46.
Quan SL, Wang W Qu XW Chen J. Controlled observation on therapeutic effects of Xuezhikang and simvastatin for treatment of hypercholesterolemia. Zhonghua Shiyong Yixue 2003;3(5):427.
Quan SL, Wang W Qu XW. The effect of Xuezhikang and simvastatin on lipid of hypercholesterolemia. China Clinical Practical Medicine 2008;2(11):91-92.
Rippe J, Bonovich K, Colfer K, and et al. A multi-center, self-controlled study of Cholestin in subjects with elevated cholestrol. Abstracts of the 39th Annual Conference on Cardiovascular Disease Epidemiology and Prevention 1999;99:1123 (Abstract P88).
Shen G, Wang J Wang JF. Comparison of the effects of the herbal lipid regulator decoction, Xuezhikang and simvastatin on lipid modulation in the middle-aged and elderly subjects with hyperlipidemia. Zhongguo Jiceng Yiyao 2000;7(4):280-281.
Shen MY. Comparison of the effects of Xuezhikang and atorvastatin for treatment of hyperlipidemia. Zhonghua Shiyong Yiyao Zazhi 2003;2(5):439-440.
Shen ZW, Yu PL Sun MZ Chi JM Zhou YF Zhu XS Yang CY He CF. Prospective study of Xuezhikang for treatment of primary hyperlipidemia. Natl Med J China 1996;76(2):156-157.
Smith, D. J. and Olive, K. E. Chinese red rice-induced myopathy. South.Med J 2003;96(12):1265-1267. View abstract.
Stefanutti, C., Mazza, F., Vivenzio, A., Di, Giacomo S., Perrone, G., Serra, M., and Bucci, A. Combined treatment with Dif1stat and diet reduce plasma lipid indicators of moderate hypercholesterolemia more effectively than diet alone: a randomized trial in parallel groups. Lipids 2009;44(12):1141-1148. View abstract.
Su, M. The clinical examinations of Xue-Zhi-Kang in the treatment for hypercholesterolemia. Beijing University, Wei-Xin data 2002;
Su, M., Wang, X., Li, Y., and et al. A clinical trial of Xuezhikang capusule in the treatment of hyperlipidemia. New Chin Herb Med Clin Pharmacol 1995;6:13-16.
Su, M., Wang, X., Li, Y., and et al. The clinical observation of Xuezhikang capsule in the treatment of hyperlipidemia. Traditional Chinese Drug Research and Clinical Pharmacology 1995;6(4):13.
Su, N. W., Lin, Y. L., Lee, M. H., and Ho, C. Y. Ankaflavin from Monascus-fermented red rice exhibits selective cytotoxic effect and induces cell death on Hep G2 cells. J Agric.Food Chem 3-23-2005;53(6):1949-1954. View abstract.
Sun FF, Ding XF Wang M. Comparison of lipid-lowering effects of Xuezhikang and Zhibituo. Jiceng Yixue Luntan 2004;8(2):121-122.
Tang HL. Randomized controlled study of Diao Zhibituo for lipid modulation effect. Sichuan Yixue 2004;25(1):78-79.
Teng, S. S. and Feldheim, W. Anka and anka pigment production. J Ind Microbiol.Biotechnol 2001;26(5):280-282. View abstract.
Thompson Coon, J. S. and Ernst, E. Herbs for serum cholesterol reduction: a systematic view. J Fam.Pract. 2003;52(6):468-478. View abstract.
Wang AH, Zhang GD. Comparison of the therapeutic effects of Xuezhikang and Lescol for treatment of hyperlipidemia. Zhongguo Zonghe Yixue 2002;3(7):617-618.
Wang CW, Gao FM You L. Clinical study on the therapeutic effects of Xuezhikang for treatment of hyperlipidemia. Mudanjiang Yixueyuan Xuebao 2000;21(3):13.
Wang DG, Li D Nie ZY. Application of cost-effectiveness analysis in Xuezhikang and pravastatin for the treatment hypercholesterolemia. Zhongguo Yaoshi 2003;12(9):53-55.
Wang DG, Li D Nie ZY. Cost-effectiveness analysis on Xuezhikang and pravastatin treatment of hypercholesterolemia. Chinese Medicine 2003;12(9):53-55.
Wang LB, Qiao JJ Li YM. Clinical evaluation of Zhibituo and concentrated fish oils for treatment of hyperlipidemia. Jiamusi Yixueyuan Xuebao 1998;21(1):62-63.
Wang SH, Sun JL Liu HQ. Therapeutic observations of Xuezhikang for treatment of 60 cases of elderly with hyperlipidemia. Anhui Linchuang Zhongyi Zazhi 2003;15(6):474-475.
Wang SX. Comparison of the therapeutic effects of Xuezhikang and lovastatin. Xiandai Zhongxiyi jiehe Zazhi 2004;13(20):2707.
Wang WH. Comparison of Xuezhikang and atorvastatin efficacy of treatment of hypercholesterolemia. Journal of Practical Traditional Chinese Medicine 2006;20(3):305.
Wang XL, Hu XM. Comparison of Xuezhikang and simvastatin in regulating lipids for hypercholesterolemia. Zhongxiyi Jiehe Xinnaoxueguanbing Zazhi 2004;2(6):319-320.
Wang YF, Yang CK Xu WJ Sun L Liu B Wang GG. Xuezhikang, gemfibrozil for regulation of hyperlipidemia in elderly and insulin sensitivity. Zhongguo Xinyao Zazhi 1998;7(3):209-211.
Wang, J. J., Shieh, M. J., Kuo, S. L., Lee, C. L., and Pan, T. M. Effect of red mold rice on antifatigue and exercise-related changes in lipid peroxidation in endurance exercise. Appl.Microbiol.Biotechnol 2006;70(2):247-253. View abstract.
Wang, J. The clinical examinations of Xue-Zhi-Kang in the treatment for hypercholesterolemia. Beijing University, Wei-Xin data 2002;
Wang, J., Su, M., and Lu, Z. Clinical trial of extract of Monascus purpureus (red yeast) in the treatment of hyperlipidemia. Chin J Exp Therapeutics for Prepared Chinese Medicine 1995;12:1-5.
Wang, J., Su, M., Lu, Z., and et al. The clinical observation of Xuezhikang capsule in the treatment of hyperlipidemia. Chinese Experimental Dispensary Journal 1995;1(1):1.
Wu, L. C., Chen, Y. C., Ho, J. A., and Yang, C. S. Inhibitory effect of red koji extracts on mushroom tyrosinase. J Agric.Food Chem 7-16-2003;51(15):4240-4246. View abstract.
Xi BL, Ren JY. Effects of Xuezhikang vs. simvastatin in treating hyperlipidemia. Guowai Yixue: Xin Xueguanbing Fence 2002;29(4):233-234.
Xia CH . Comparison of lipid modification of Xuezhikang and Duoxikang in hyperlipidemia. Suzhou Yixueyuan Xuebao 1999;19(9):1015-1016.
Xiao CL, Yao ZQ He SM. Comparison of the lipid modification effects of Xuezhikang and Zhibituo for hypercholesterolemia. Guangdong Yixue Zazhi 2000;21(5):430-431.
Xiao M, Ye P. Clinical observation of Xuezhikang for treatment of hyperlipidemia. Shuli Yixue Zazhi 2001;14(3):244-245.
Xu CB, Hu DY Kang LP Tian YW Gao MM Xu ZM Jin SY Ma FY Ma M Shi XY Zhang BH Long NZ Li L Xue L Zhang JH Chen XL Dai CX. Comparative study of relatively long-term therapy for dyslipidemia with low-dose Xuezhikang or pravastatin in Chinese patients. Zhongguo Yaoxue 2000;9(4):218-222.
Xu JM, Chen SX Hu WY Cai NS Xu Q Wu ZG Sun KX. Zhibituo vs. placebo treatment of hyperlipidemia a double blind randomized and multicenter study. Zhongguo Xinyao Yu Linchuang Zazhi 1997;16(1):47-51.
Xu SG. Analysis of therapeutic effect of Xuezhikang for treatment of primary hypercholesterolemia. Henon Yixue Xinxi 2002;10(13):6-7.
Xu WY, Yan YZ Tang ZH. Therapeutic observations on Xuezhikang capsules for treatment of hyperlipidemia. Haixia Yaoxue 2003;15(2):65-66.
Yan HD, Guo JH Jia ST. Observations of the short-term effects of Probucol in treatment of hyperlipidemia. Shanxi Linchuang Yixue 1999;8(2):103-104.
Yang MJ, Wang RZ. Zhibituo for treatment of 100 cases of hyperlipidemia. Zhongguo Xinyao Yu Linchuang Zazhi 1997;16(1):9-10.
Yang Q, Xue HQ. Observations on the therapeutic effects of Zhibituo for treatment of hyperlipidemia. Zhongguo Jiceng Yiyao 1999;6(3):129.
Yang SS. Xuezhikang for treatment of 76 patients with hyperlipidemia. Zhongchengyao 2002;24(10):815-816.
Yang WJ, Fu XJ. Comparison of the therapeutic effects of Zhibituo and simvastatin for treatment of hyperlipidemia. Zhongguo Xiandai Yiyao Yu Jishu 2003;3(2):2-4.
Yang, N. C., Chou, C. W., Chen, C. Y., Hwang, K. L., and Yang, Y. C. Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia. Asia Pac.J.Clin.Nutr. 2009;18(3):310-317. View abstract.
Ye, P., Lu, Z. L., Du, B. M., Chen, Z., Wu, Y. F., Yu, X. H., and Zhao, Y. C. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study. J.Am.Geriatr.Soc. 2007;55(7):1015-1022. View abstract.
Yu CY, Zhang C Yang H Jin W. Observations of therapeutic effects of Xuezhikang for treatment of primary hyperlipidemia. Heilongjiang Yixue Zazhi 2004;17(2):151-152.
Yu HY, Li TH. Observations on the therapeutic effects of Zhibituo for treatment of hyperlipidemia. Xinxueguan Kangfu Yixue Zazhi 1999;8(1):30-31.
Zeng TK. Observation of the therapeutic effects of Xuezhikang for treatment of 77 elderly with hyperlipidemia. Shoudu Yiyao 1999;6(11):49.
Zhang G, M XY C XB H X M JK W MH. Study of Xuezhikang and atorvastatin on mixed type hyperlipidemia. Modern Journal of Integrated Traditional Chinese and Western Medicine 2005;14(2):154-155.
Zhang G, Zhang KX Xu Z Guang XF. Comparison of lipid-lowering effects of Xuezhikang and Simvastatin for hyperlipidemia. Shoudu Yiyao 1998;5(6):35-36.
Zhang GR . Comparison of Zhibituo and simvastatin for their effects on hyperlipidemia. Guangxi Yixue 2002;24(5):713-714.
Zhang JS . Comparison of Xuezhikang and inositol nicotinate for treatment of hyperlipidemia. Zhiye Yu Jiankang 2002;18(1):138-140.
Zhang QL. Comparative interventional therapies of dyslipidemia by simvastatin and Zhibituo with 60 cases. Guoji Yiyao Weisheng Daobao 2004;10(10):29-30.
Zhang WM, Yang JX Li F Zhang GW. Observations of Xuezhikang in treatment of hyperlipidemia and abnormal haemorheology. Henan Shiyong Shenjingbing Zazhi 2000;3(3):47-48.
Zhao XH, Jiang XM Ao LJ. Therapeutic observations of Xuezhikang for treatment of hyperlipidemia. Yunnan Yiyao 1998;19(1):26.
Zhao YL, Ouyang HB. Observation on therapeutic effects of Zhibituo for treatment of hyperlipidemia. Changchun Yixue Zazhi 1998;11(1):21.
Zhao, S. P., Liu, L., Cheng, Y. C., Shishehbor, M. H., Liu, M. H., Peng, D. Q., and Li, Y. L. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 8-24-2004;110(8):915-920. View abstract.
Zheng CJ, Wang P. Zhibituo vs. simvastatin in treatment of hyperlipidemia. Zhongguo Yaoshi 2001;4(6):447-448.
Zheng FS, Long XD Liu HM Liu YL Bao YZ Yu M. Comparison of lovastatin and Chinese Xuezhikang in lipid modification for primary hyperlipidemia. Yunan Yixue 2000;21(5):442-443.
Zheng H, Dan XY Ning H Xue B. Observations of Xuezhikang on clinical effects and haemorheology. Hebei Yiyao 2001;7(1):46-48.
Zheng JR, Wang B. Effects of Xuezhikang on treatment of primary hyperlipidemia. Yixue Luntan Zazhi 2004;25(14):21-22.
Zheng Y, Luo XZ Wang SL Yang YJ. Clinical controlled study on the therapeutic effects of Xuezhikang and Simvastatin. Zhongguo Yaoshi 2001;36(10):715.
Zhiwei, S. A prospective study on Zhitai capsule in the treatment of primary hyperlipidemia. Natl Med J China 1996;76:156-157.
Zhou ZL, Liu CH. Xuezhikang for treatment of 20 cases of hyperlipidemia. Hunan Zhongyiyao Daobao 1999;5(7):25.
Zhu QF, Jiang L Wang Y. Effects of Xuezhikang and simvastatin on apolipoprotein B and A1 in patients with hyperlipidemia. Guangming Zhongyi 2003;18(5):24-25.
Zhu WM, Wu SR. Effects and safety of combined treatment by Xuezhikang and micronized fenofibrate in patients with hyperlipidemia. Zhongguo Linchuang Yixue Zazhi 2003;4(2):18-20.
Anon. Court backs Food & Drug Administration's check of cholestin. NewsExcite.com. news.excite.com/news/ap/000723/19/cholesterol-dispute (Accessed 25 July 2000).
Bargossi AM, Battino M, Gaddi A, et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res 1994;24:171-6. View abstract.
Barrat E, Zaïr Y, Ogier N, et al. A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial. Int J Food Sci Nutr. 2013;64(7):882-9. View abstract.
Barrat E, Zaïr Y, Sirvent P, et al. Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study. Eur J Nutr. 2013;52(8):1843-52. View abstract.
Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: A randomized trial. Ann Intern Med 2009;150:830-9. View abstract.
Blanc PJ, Laussac JP, Le Bars J, et al. Characterization of monascidin A from Monascus as citrinin. Int J Food Microbiol. 1995;27(2-3):201-213. View abstract.
Bliznakov EG. More on the Chinese red-yeast-rice supplement and its cholesterol-lowering effect. Am J Clin Nutr 2000;71:152-7. View abstract.
Bogsrud, M. P., Ose, L., Langslet, G., Ottestad, I., Strom, E. C., Hagve, T. A., and Retterstol, K. HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Scand.Cardiovasc.J. 2010;44(4):197-200. View abstract.
Chen CL, Tseng JH, Pan TM, Hsiao SH. A Randomized, Double-Blind Clinical Study on Blood Pressure Reduction and Blood Lipid Profile Amelioration on Treatment with Ankascin 568. Chin J Physiol. 2017;60(3):158-165. View abstract.
Chen TL, Yeh CC, Lin CS, Shih CC, Liao CC. Effects of red yeast rice prescription (LipoCol Forte) on adverse outcomes of surgery. QJM. 2019;112(4):253-259. View abstract.
Cicero, AF, Rovati LC, and Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung. 2007;57:26-30. View abstract.
Cohen PA, Avula B, Khan IA. Variability in strength of red yeast rice supplements purchased from mainstream retailers. Eur J Prev Cardiol. 2017;24(13):1431-1434. doi: 10.1177/2047487317715714. View abstract.
Fang, Y. and Li, W. Effect of xuezhikang on lipid metabolism and Islet 3 cell function in type II diabetic patients. Journal of Capital Medicine 2000;7(2):44-45.
Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4. View abstract.
Fu, H. and Zhang, B. Effect of xuezhikang on hyperlipidemia of chronic renal failure patients with peritoneal dialysis. Chinese New Drug Journal 1998;7(3):211-213.
Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis. 2015;240(2):415-23. doi: 10.1016/j.atherosclerosis.2015.04.004. View abstract.
Gheith, O., Sheashaa, H., Abdelsalam, M., Shoeir, Z., and Sobh, M. Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidemia: a preliminary report. Eur J Intern Med 2009;20(3):e57-e61. View abstract.
Gheith, O., Sheashaa, H., Abdelsalam, M., Shoeir, Z., and Sobh, M. Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia. Clin Exp Nephrol 2008;12(3):189-194. View abstract.
Heber D, Lembertas A, Lu QY, et al. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001;7:133-9. View abstract.
Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-6. View abstract.
Huang HN, Hua YY, Bao GR, Xie LH. The quantification of monacolin K in some red yeast rice from Fujian province and the comparison of the other product. Chem Pharm Bull (Tokyo) 2006;54:687-9. View abstract.
Huang, C. F., Li, T. C., Lin, C. C., Liu, C. S., Shih, H. C., and Lai, M. M. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil 2007;14(3):438-440. View abstract.
Huang, J., Frohlich, J., and Ignaszewski, A. P. The impact of dietary changes and dietary supplements on lipid profile. Can J Cardiol 2011;27(4):488-505. View abstract.
Jin W, Yang H, Zhang C, et al. A COMPARATIVE STUDY OF XUEZHIKANG AND MEVALOTIN IN TREATMENT OF ESSENTIAL HYPERLIPIDEMIA. Chinese Journal of New Drugs 1997;6:265-268.
Kantola T, Kivisto KT, Neuvonen PJ, et al. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998 63:397-402. View abstract.
Karl M, Rubenstein M, Rudnick C, Brejda J. A multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability). J Clin Lipidology 2012;6:150-158. View abstract.
Kasliwal RR, Bansal M, Gupta R, et al. ESSENS dyslipidemia: a placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. Nutrition. 2016;32(7-8):767-76. doi: 10.1016/j.nut.2016.01.012.View abstract.
Keithley J, Swanson G, Kessler H, and et al. A pilot study of the safety and efficacy of Cholestin® in treating HIV-related dylipidemia. Altern Ther Health Med 2001;7(3):s18.
Keithley JK, Swanson B, Sha BE, et al. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition 2002;18:201-4.. View abstract.
Kou W, Lu Z, Guo J. [Effect of xuezhikang on the treatment of primary hyperlipidemia]. Zhonghua Nei Ke Za Zhi 1997;36:529-31. View abstract.
Kumari S, Sherriff JM, Spooner D, Beckett R. Peripheral neuropathy induced by red yeast rice in a patient with a known small bowel gastrointestinal tumour. BMJ Case Rep. 2013;2013. View abstract.
Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol 2008;66:572-74. View abstract.
Li YG, Zhang F, Wang ZT, et al. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed.Anal. 9-3-2004;35(5):1101-1112. View abstract.
Li, J. J., Lu, Z. L., Kou, W. R., Chen, Z., Wu, Y. F., Yu, X. H., and Zhao, Y. C. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol 2009;49(8):947-956. View abstract.
Li, J. J., Lu, Z. L., Kou, W. R., Chen, Z., Wu, Y. F., Yu, X. H., and Zhao, Y. C. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Ann Med 2010;42(3):231-240. View abstract.
Li, J. J., Lu, Z. L., Kou, W. R., Chen, Z., Wu, Y. F., Yu, X. H., and Zhao, Y. C. Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS). Clin Exp Hypertens 2010;32(8):491-498. View abstract.
Lin, C. C., Li, T. C., and Lai, M. M. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 2005;153(5):679-686. View abstract.
Liu J, Zhang J, Shi Y, et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006;1:4. View abstract.
Liu SF, Wang YR, Shen YC, et al. A randomized, double-blind clinical study of the effects of Ankascin 568 plus on blood lipid regulation. J Food Drug Anal. 2018;26(1):393-400. View abstract.
Liu, L., Zhao, S. P., Cheng, Y. C., and Li, Y. L. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem 2003;49(8):1347-1352. View abstract.
Liu, Z. L., Liu, J. P., Zhang, A. L., Wu, Q., Ruan, Y., Lewith, G., and Visconte, D. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev 2011;(7):CD008305. View abstract.
Lu, G., Shen, Y., and Lansheng, G. Comparison of the effects of Xuezhikang and Simvastatin on lipid profile modification in patients with hypercholesterolemia. Chin J Intern Med 1998;37(6)
Lu, L., Zhou, J. Z., Wang, L., and Zhang, T. X. Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension. Chin J Integr Med 2009;15(4):266-271. View abstract.
Lu, Z., Kou, W., Du, B., Wu, Y., Zhao, S., Brusco, O. A., Morgan, J. M., Capuzzi, D. M., and Li, S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008;101(12):1689-1693. View abstract.
Lu, Z., Kou, W., Qiu, Z., and et al. Clinical observation of xuezhikangon treatment of hyperlipidemia. Chinese Circulation Journal 1997;12(1):12-15.
Ma J, Li Y, Ye Q, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric.Food Chem. 2000;48(11):5220-5225. View abstract.
Marazzi G, Campolongo G, Pelliccia F, Quattrino S, Vitale C, Cacciotti L, et al. Comparison of low-dose statin versus low-dose statin + Armolipid plus in high-intensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE trial). Am J Cardiol. 2017 Sep 15;120(6):893-897. doi: 10.1016/j.amjcard.2017.06.015. View abstract.
Marazzi G, Pelliccia F, Campolongo G, Quattrino S, Cacciotti L, Volterrani M, et al. Usefulness of nutraceuticals (Armolipid Plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease. Am J Cardiol. 2015 Dec 15;116(12):1798-801. doi: 10.1016/j.amjcard.2015.09.023. View abstract.
Mazza A, Lenti S, Schiavon L, et al. Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome. Biomed Pharmacother 2018;105:992-6. doi: 10.1016/j.biopha.2018.06.076. View abstract.
Mazzanti G, Moro PA, Raschi E, Da Cas R, Menniti-Ippolito F. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol 2017;83(4):894-908. doi: 10.1111/bcp.13171. View abstract.
Mazzanti G, Moro PA, Raschi E, Da Cas R, Menniti-Ippolito F. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017 Jan 17. doi: 10.1111/bcp.13171. [Epub ahead of print] View abstract.
Mercurio V, Pucci G, Bosso G, et al. A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Nutr. 2020;39(5):1379-1384. View abstract.
Millán J, Cicero AF, Torres F, Anguera A. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomized controlled trials. Clin Investig Arterioscler. 2016;28(4):178-87. View abstract.
Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18:S137-S144. View abstract.
Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med 2006;145:474-5. View abstract.
Ogier N, Amiot MJ, Georgé S, et al. LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. Eur J Nutr. 2013;52(2):547-57. View abstract.
Patrick, L. and Uzick, M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev 2001;6(3):248-271. View abstract.
Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000;355:547-8. View abstract.
Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002;74:1200-1. View abstract.
Prescribing Information. Mevacor (lovastatin). Whitehouse Station, NJ: Merck & Co., Inc., February 2012.
Raschi E, Girardi A, Poluzzi E, et al. Adverse events to food supplements containing red yeast rice: comparative analysis of FAERS and CAERS reporting systems. Drug Saf 2018;41(8):745-52. doi: 10.1007/s40264-018-0661-3. View abstract.
Robbers JE, Tyler VE. Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York, NY: The Haworth Herbal Press, 1999.
Rogers JD, Zhao J, Liu L, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999;66:358-66. View abstract.
Roselle H, Ekatan A, Tzeng J, et al. Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med 2008;149:516-7. View abstract.
Ruscica M, Gomaraschi M, Mombelli G, Macchi C, Bosisio R, Pazzucconi F, Pavanello C, Calabresi L, Arnoldi A, Sirtori CR, Magni P. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol. 2014;8(1):61-8. View abstract.
Safety of red yeast rice. Pharmacist's Letter / Prescriber's Letter 2008;24(12):241203.
Shen, Z., Yu, P., Sun, M., and et al. [A prospective study on Zhitai capsule in the treatment of primary hyperlipidemia] (Translation). National Medical Journal of China 1996;76(2):156-158.
Sungthong B, Yoothaekool C, Promphamorn S, Phimarn W. Efficacy of red yeast rice extract on myocardial infarction patients with borderline hypercholesterolemia: A meta-analysis of randomized controlled trials. Sci Rep. 2020;10(1):2769. View abstract.
US Dept Health, Human Services, FDA. Pharmanex, Inc, administrative proceeding, public docket #97P-0441: final decision. Available at: www.fda.gov/ohrms/dockets/dockets/97p0441/ans0002.pdf
Venhuis BJ, van Hunsel F, van de Koppel S, Keizers PH, Jeurissen SM, De Kaste D. Pharmacologically effective red yeast rice preparations marketed as dietary supplements illustrated by a case report. Drug Test Anal. 2016;8(3-4):315-8. doi: 10.1002/dta.1929. View abstract.
Vercelli, L., Mongini, T., Olivero, N., Rodolico, C., Musumeci, O., and Palmucci, L. Chinese red rice depletes muscle coenzyme Q10 and maintains muscle damage after discontinuation of statin treatment. J Am Geriatr Soc 2006;54(4):718-720. View abstract.
Wang J, Lu A, Chi J. Multicenter clinical trial of the serum lipid-lowering effects of a monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Cur Ther Res 1997;58:964-78.
Wang YR, Liu SF, Shen YC, et al. A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation. J Food Drug Anal. 2017;25(2):409-416. View abstract.
Wang, J., Lu, Z., Chi, J., and et al. Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Current Therapeutic Research 1997;58(12):964-978.
Wang, W. H., Zhang, H., Yu, Y. L., Ge, Z., Xue, C., and Zhang, P. [Intervention of xuezhikang on patients of acute coronary syndrome with different levels of blood lipids]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004;24(12):1073-1076. View abstract.
Wigger-Alberti W, Bauer A, Hipler UC, Elsner P. Anaphylaxis due to Monascus purpureus-fermented rice (red yeast rice). Allergy 1999;54:1330-1. View abstract.
Xie, J. P., Liu, G. L., Qiao, J. L., Gu, Q., Gai, Y. N., Huang, S. F., Gao, A. A., Zhou, Y., Li, X. H., Wang, C. Y., Liu, R. Q., and Jia, J. J. [Multi-central randomized controlled study on electroacupuncture at Fenglong (ST 40) for regulating blood lipids]. Zhongguo Zhen Jiu 2009;29(5):345-348. View abstract.
Xie, X., Meng, X., Zhou, X., Shu, X., and Kong, H. [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. Zhongguo Zhong Yao Za Zhi 2011;36(21):3032-3035. View abstract.
Ye, P., Wu, C. E., Sheng, L., and Li, H. Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension. J Altern Complement Med 2009;15(7):719-725. View abstract.
Yu P, Shen Z, Sun M, et al. A clinical study of Xuezhikang on the treatment of primary hyperlipidemia. Chinese Circulation Journal 1997;12(1):16-19.
Yu, P., Shen, Z., Chi, J., and Yang, C. Clinical observation of the effects of xuezhikang on older primary hyperlipidemia patients. Chinese Journal of Geriatrics 1996;16:206-208.
Zhao, S. P., Liu, L., Cheng, Y. C., and Li, Y. L. Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. Atherosclerosis 2003;168(2):375-380. View abstract.
Zhao, S. P., Lu, Z. L., Du, B. M., Chen, Z., Wu, Y. F., Yu, X. H., Zhao, Y. C., Liu, L., Ye, H. J., and Wu, Z. H. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS). J Cardiovasc Pharmacol 2007;49(2):81-84. View abstract.
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.